# A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

> **NCT06118411** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 614 (actual)

## Conditions studied

- Vitiligo

## Interventions

- **DRUG:** Upadacitinib
- **DRUG:** Placebo
- **OTHER:** NB-UVB (narrow-band ultraviolet B) Phototherapy

## Key facts

- **NCT ID:** NCT06118411
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-19
- **Primary completion:** 2025-09-23
- **Final completion:** 2028-02
- **Target enrollment:** 614 (ACTUAL)
- **Last updated:** 2025-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06118411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06118411, "A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06118411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*